lin kun

Dr. lin kun

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2024 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
YDYang Ding
Yang Ding
YNYumei Ning
Yumei Ning
HKHui Kang
Hui Kang
YYYuan Yuan
Yuan Yuan
LKlin kun
lin kun
Ying ChangYing Chang
Ying Chang
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies with a high lethality rate. ZMIZ2 is a transcriptional co-activator implicated in various human diseases. However, the role and molecular mechanism of ZMIZ2 in HCC remains to be elucidated. Methods: The expression and prognostic value of ZMIZ2 in HCC was excavated from public databases and explored by bioinformatic analysis. Then the expression of ZMIZ2 and related genes was further validated by quantitative RT-PCR, western blotting, and immunohistochemistry. Loss and gain-of-function experiments were performed in vitro and in vivo to investigate the function of ZMIZ2 in HCC. In addition, transcriptome sequencing and immunoprecipitation was conducted to explore the potential molecular mechanisms of ZMIZ2. Results: ZMIZ2 was highly expressed in HCC and associated with poor prognosis. Silencing ZMIZ2 significantly inhibited HCC cell proliferation, cell cycle process, migration, and invasion in vitro, and also inhibited the progression of HCC in vivo. Additionally, ZMIZ2 expression was correlated with immune cell infiltration in HCC samples. Somatic mutation analysis showed that ZMIZ2 and TP53 mutations jointly affected the progression of HCC. Mechanistically, ZMIZ2 interacted with LEF1 to regulate malignant progression of HCC by activating the Wnt/β-catenin pathway. Conclusion: ZMIZ2 was overexpressed in HCC and associated with poor prognosis. The overexpression of ZMIZ2 was corelated with malignant phenotype, and it facilitated HCC progression via LEF1-mediated activation of the Wnt/β-catenin pathway. Furthermore, ZMIZ2 could be served as a prognostic biomarker and a new therapeutic target for HCC.

8 October 2021 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
LZLu Zhuang
Lu Zhuang
YYYao Yao
Yao Yao
LPLisi Peng
Lisi Peng
FCFang Cui
Fang Cui
CCCui Chen
Cui Chen
LKlin kun
lin kun

7 October 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
ZHZilin Huang
Zilin Huang
QXQiang Xie
Qiang Xie
SLShuang Li
Shuang Li
YZYuhao Zhou
Yuhao Zhou
ZHzuhong he
zuhong he
XCXiong Chen
Xiong Chen
Hearing loss is one of the most common disabilities affecting both children and adults worldwide. However, traditional treatment of hearing loss has some limitations, particularly in terms of drug delivery system as well as diagnosis of ear imaging. The blood–labyrinth barrier (BLB), the barrier between the vasculature and fluids of the inner ear, restricts entry of most blood-borne compounds into inner ear tissues. Nanoparticles (NPs) have been demonstrated to have high biocompatibility, good degradation, and simple synthesis in the process of diagnosis and treatment, which are promising for medical applications in hearing loss. Although previous studies have shown that NPs have promising applications in the field of inner ear diseases, there is still a gap between biological research and clinical application. In this paper, we aim to summarize developments and challenges of NPs in diagnostics and treatment of hearing loss in recent years. This review may be useful to raise otology researchers’ awareness of effect of NPs on hearing diagnosis and treatment.

20 April 2026 in Oncogene
Verified
Journal Article
Closed access
CLChushu Li
Chushu Li
SDShouyan Deng
Shouyan Deng
MZMinxian Zhuang
Minxian Zhuang
TLTihui Li
Tihui Li
LLLiying Lin
Liying Lin
FCFenglin Chen
Fenglin Chen

11 November 2026 in Research Square
Verified
Preprint
Open access
PDF file
LLLan Liu
Lan Liu
FHFengxing Huang
Fengxing Huang
YSYu Shao
Yu Shao
YWYouwei Wang
Youwei Wang
RZRunan Zhang
Runan Zhang
QZQiu Zhao
Qiu Zhao
Lipid metabolic reprogramming is a key feature of colorectal cancer (CRC), yet how CRC cells tolerate lipid overload and evade lipotoxic cell death remains incompletely understood. This study reveals that the ELAVL1/HMGCR/lipid-droplet axis supports CRC cell survival under lipid-rich conditions. Fatty-acid exposure, high-fat diet, and tumor-associated metabolic remodeling promoted cytoplasmic translocation of the RNA-binding protein ELAVL1, accompanied by lipid droplet accumulation in CRC. ELAVL1 depletion impaired triglyceride and cholesterol ester storage, reduced lipid-droplet biogenesis, and sensitized CRC cells to endoplasmic reticulum stress, mitochondrial fragmentation, membrane damage, reactive oxygen species accumulation, and apoptosis. Conversely, ELAVL1 overexpression enhanced neutral-lipid storage and protected cells from lipotoxic damage. Mechanistically, ELAVL1 binds the 3′UTR of HMGCR mRNA and enhances its stability, thereby maintaining the cholesterol/mevalonate pathway. In ELAVL1-deficient cells, restoration of HMGCR rescued lipid droplet formation, lipid homeostasis, and organelle integrity, whereas inhibition of HMGCR abolished ELAVL1-driven lipid droplet expansion and cytoprotective effects. In high-fat-diet-associated CRC models, ELAVL1 inhibition suppressed lipid-droplet accumulation, whereas combined ELAVL1/HMGCR targeting disrupted lipid homeostasis, enhanced apoptosis, and reduced tumor burden. These findings suggest that ELAVL1-mediated stabilization of HMGCR mRNA promotes lipid-droplet buffering, thereby protecting CRC cells from lipotoxic cell death, and point to a targetable vulnerability in colorectal cancer therapy.